Effect of Hypovitaminosis D on Lipid Profile in Hypothyroid Patients in Saudi Arabia.
Adult
Body Mass Index
Cholesterol
/ blood
Cholesterol, LDL
/ blood
Enzyme-Linked Immunosorbent Assay
Female
Humans
Hypothyroidism
/ blood
Lipids
/ blood
Lipoproteins, LDL
/ metabolism
Male
Middle Aged
Retrospective Studies
Risk Factors
Saudi Arabia
Thyrotropin
/ metabolism
Triglycerides
/ blood
Vitamin D
/ blood
Vitamin D Deficiency
/ blood
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
11
2020
revised:
04
12
2020
accepted:
10
12
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Hypothyroidism is believed to be associated with dyslipidemia and is considered a risk factor for the development of atherosclerotic cardiovascular diseases (ASCVD). Vitamin D, due to its steroid hormone action, retains cell function and controls the metabolism of lipids. Therefore, the present study was carried out to show the association of the risk factors of ASCVD and deficiency of thyroid hormones and vitamin D levels since no previous studies have been performed on Saudi patients before. Total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels were significantly higher in hypothyroid patients than those in the normal group. We have found a significant correlation between TSH levels and the risk factors of ASCVD (total cholesterol, triglycerides, and LDL-C). Moreover, a significant correlation between vitamin D levels and the risk factors of ASCVD (total cholesterol, triglycerides, and LDL-C) has been found. In addition, there is a correlation between deficiency of Vit D and low-TSH levels (95% CI 1.092-4.05) indicating a higher risk for the development of ASCVD among those patients. Hypothyroid and vitamin D-deficient patients must be screened regularly at an early stage to predict and also to prevent cardiovascular diseases. Moreover, an adequate supply of vitamin D and TH should be given to those patients to prevent cardiovascular diseases at an early stage.
Sections du résumé
BACKGROUND
BACKGROUND
Hypothyroidism is believed to be associated with dyslipidemia and is considered a risk factor for the development of atherosclerotic cardiovascular diseases (ASCVD). Vitamin D, due to its steroid hormone action, retains cell function and controls the metabolism of lipids. Therefore, the present study was carried out to show the association of the risk factors of ASCVD and deficiency of thyroid hormones and vitamin D levels since no previous studies have been performed on Saudi patients before.
RESULT
RESULTS
Total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels were significantly higher in hypothyroid patients than those in the normal group. We have found a significant correlation between TSH levels and the risk factors of ASCVD (total cholesterol, triglycerides, and LDL-C). Moreover, a significant correlation between vitamin D levels and the risk factors of ASCVD (total cholesterol, triglycerides, and LDL-C) has been found. In addition, there is a correlation between deficiency of Vit D and low-TSH levels (95% CI 1.092-4.05) indicating a higher risk for the development of ASCVD among those patients.
CONCLUSION
CONCLUSIONS
Hypothyroid and vitamin D-deficient patients must be screened regularly at an early stage to predict and also to prevent cardiovascular diseases. Moreover, an adequate supply of vitamin D and TH should be given to those patients to prevent cardiovascular diseases at an early stage.
Identifiants
pubmed: 33425213
doi: 10.1155/2020/6640402
pmc: PMC7775159
doi:
Substances chimiques
Cholesterol, LDL
0
Lipids
0
Lipoproteins, LDL
0
Triglycerides
0
Vitamin D
1406-16-2
Thyrotropin
9002-71-5
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6640402Informations de copyright
Copyright © 2020 Awad S. Alsamghan et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Nutr Hosp. 2017 Mar 30;34(2):323-329
pubmed: 28421785
Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E315-22
pubmed: 16507601
Med Clin North Am. 2012 Mar;96(2):269-81
pubmed: 22443975
J Am Coll Cardiol. 2001 Aug;38(2):307-14
pubmed: 11499717
Pharmacol Res. 2016 Nov;113(Pt A):600-609
pubmed: 27697647
J Clin Res Pediatr Endocrinol. 2013;5 Suppl 1:40-4
pubmed: 23149391
J Family Med Prim Care. 2020 Jan 28;9(1):147-150
pubmed: 32110581
Diabetes Metab Syndr. 2016 Apr-Jun;10(2):105-12
pubmed: 25813139
J Atheroscler Thromb. 2016;23(3):266-75
pubmed: 26558400
Arch Osteoporos. 2012;7:155-72
pubmed: 23225293
J Cardiovasc Med (Hagerstown). 2018 Feb;19(2):62-66
pubmed: 29252600
Arq Bras Endocrinol Metabol. 2014 Jul;58(5):411-33
pubmed: 25166032
Circulation. 2007 Oct 9;116(15):1725-35
pubmed: 17923583
Obes Surg. 2005 Oct;15(9):1287-91
pubmed: 16259889
Endocr J. 2011;58(5):349-54
pubmed: 21490407
J Clin Endocrinol Metab. 2011 Jan;96(1):53-8
pubmed: 21118827
Int J Occup Med Environ Health. 2016;29(5):859-70
pubmed: 27518893
BMC Public Health. 2017 Jun 22;17(1):519
pubmed: 28637448
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Circulation. 2016 Jun 14;133(24):2459-502
pubmed: 27297342
Eur J Pharmacol. 2015 Jan 15;747:18-28
pubmed: 25489922
Int J Health Sci (Qassim). 2013 Nov;7(3):267-75
pubmed: 24533019
J Steroid Biochem Mol Biol. 2017 Oct;173:258-264
pubmed: 28007531
Nat Rev Endocrinol. 2018 May;14(5):259-269
pubmed: 29472712
Nat Rev Cardiol. 2017 Jan;14(1):39-55
pubmed: 27811932
BMC Public Health. 2019 Nov 11;19(1):1500
pubmed: 31711454
Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1651-9
pubmed: 27255724
Methodist Debakey Cardiovasc J. 2017 Apr-Jun;13(2):55-59
pubmed: 28740582
Public Health Nutr. 2017 Nov;20(16):2878-2886
pubmed: 28829285
Lipids Health Dis. 2018 Jun 5;17(1):134
pubmed: 29871648
Thyroid. 2002 Apr;12(4):287-93
pubmed: 12034052
Int J Mol Sci. 2020 May 16;21(10):
pubmed: 32429489
Ann Intern Med. 2008 Jun 3;148(11):832-45
pubmed: 18490668
PLoS One. 2009 Jun 19;4(6):e5988
pubmed: 19543524
Public Health Nutr. 2018 Aug;21(11):2004-2012
pubmed: 29478422
Cureus. 2019 Nov 16;11(11):e6173
pubmed: 31890380
J Physiol Biochem. 2015 Jun;71(2):289-99
pubmed: 25929726
J Investig Med. 2012 Jan;60(1):23-8
pubmed: 21997314
Int J Biomed Sci. 2011 Dec;7(4):238-48
pubmed: 23675242
Curr Med Res Opin. 2019 Jun;35(6):1059-1063
pubmed: 30479168
Eur J Clin Nutr. 2015 Mar;69(3):291-6
pubmed: 25514898
Arch Biochem Biophys. 2011 Mar 15;507(2):241-7
pubmed: 21176770
Mol Cell Biochem. 2015 Oct;408(1-2):235-43
pubmed: 26160278
J Clin Endocrinol Metab. 2008 Aug;93(8):2998-3007
pubmed: 18505765
Open Cardiovasc Med J. 2011;5:76-84
pubmed: 21660244
Obes Rev. 2012 Mar;13(3):275-86
pubmed: 22106927
Int J Mol Sci. 2018 Sep 13;19(9):
pubmed: 30216977
J Cell Physiol. 2019 Nov;234(11):21352-21358
pubmed: 31173353
Arch Physiol Biochem. 2019 Jul 10;:1-15
pubmed: 31291127